Dr. Richard Gilfillan, the 1st leader of the recently-created Center for Medicare & Medicaid Services Innovation Center, will hand over the reigns at the end of the month, and no replacement has yet been named.
The CMS Innovation Center was formed as part of the Affordable Care Act and tasked with reforming healthcare delivery and reducing costs. Gilfillan was appointed director in 2010, taken from his position as CEO of Geisinger Health Plan. At Geisinger, he directed insurance operations for the company’s health system and developed a system called ProvenCare that tied reimbursement to medical outcomes.
Gilfillan will leave the organization at the end of this month and plans to seek out "new opportunities," according to an internal memo obtained by Politico.
Nephros swaps CFOs
CFO Gerald Kochanski, who earlier this year put in his two weeks notice at Nephros Inc. (OTC:NEPH), was replaced last month by Marc Panoff, who was most recently the senior partner and vice president of finance of a large media investment group.
Greenberg Traurig adds 2 to life science and medtech group
The law firm Greenberg Traurig appointed David Dykeman and David Peck as co-chairs of the its life science and medical technology group. Dykeman and Peck will head the firm’s attorney group that provides litigation, IP, and government regulation services to life science, medtech and healthcare industries. The new co-chairs are both shareholders in the international LLP and were hired from within the company.
K2M promotes an industry vet to VP of global sales
Gianluca Iasci, the former international VP at K2M, was promoted to executive VP of global sales. Iasci moved over to the spinal device company after 12 years at Johnson & Johnson (NYSE:JNJ). Iasci also previously worked at AGA Medical, Boston Scientific (NYSE:BSX) and St. Jude Medical (NYSE:STJ). Read more
LifeScience Alley pulls new board members from top device companies
The device industry trade group LifeScience Alley recently pulled in 5 new board members from top device companies. The new board members include Kathleen Chester, VP of global regulatory affairs at St. Jude; Todd Fruchterman, senior VP of R&D and CMO of 3M Co. (NYSE:MMM); Brian Herman, VP of research at the University of Minnesota; Rick Kuntz, chief science, regulatory and clinical officer at Medtronic (NYSE:MDT); and Jeff Mirviss, senior VP and president of Peripheral Interventions at Boston Scientific.
LifeScience Alley also shuffled its board leadership as outgoing chairman Steve Mertens stepped over to serve as vice chair and current vice chair Stephen Snyder stepped up as chairman.